TargetMol

Vardenafil hydrochloride trihydrate

Product Code:
 
TAR-T4097
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T4097-5mg5mg£102.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4097-1mL1 mL * 10 mM (in DMSO)£116.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4097-10mg10mg£122.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4097-25mg25mg£173.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4097-50mg50mg£229.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4097-100mg100mg£322.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4097-200mg200mg£446.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4097-500mg500mg£675.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Vardenafil HCl Trihydrate is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively.
CAS:
330808-88-3
Formula:
C23H39ClN6O7S
Molecular Weight:
579.11
Pathway:
Metabolism
Purity:
0.9966
SMILES:
O.O.O.Cl.CCCc1nc(C)c2n1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1
Target:
PDE

References

Saenz de Tejada I, et al. Int J Impot Res, 2001, 13(5), 282-290. Ferrini MG, et al. Urology, 2006, 68(2), 429-435. Blount MA, et al. Mol Pharmacol, 2004, 66(1), 144-152. Salloum FN, et al. J Mol Cell Cardiol, 2007, 42(2), 453-458. Prickaerts J, et al. Neuroscience, 2002, 113(2), 351-361.